Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2024-04-26 Interim / Quarterly Rep…
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT Q1 2024' for Nanologica AB. It contains comprehensive financial statements, including a financial summary, key figures (group), and a detailed CEO comment on business performance for the first quarter of 2024. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2024
2024-04-26 English
Notice Convening the Annual General Meeting of Nanologica AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice Convening the Annual General Meeting of Nanologica AB (publ)" and details the date, time, location, right to attend, proxy rules, and a detailed agenda for the meeting. The agenda items (e.g., election of chairman, approval of financial statements, determination of fees, election of the Board/auditor, resolution on remuneration report, issue authorization) are standard components of an Annual General Meeting (AGM) notice. This clearly identifies the document as material related to the AGM. Although it mentions the Annual Report (Item 6), the document itself is the notice summoning shareholders to vote on the matters presented, which aligns best with the AGM-R category, which covers presentations and materials shared during the AGM.
2024-04-10 English
Kallelse till årsstämma i Nanologica AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Nanologica AB (publ)" which translates to "Notice of Annual General Meeting in Nanologica AB (publ)". It details the date, time, location, registration requirements, agenda items (including election of board members, approval of financial statements, remuneration reports, and capital structure changes), and proposed resolutions for the meeting. This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2024-04-10 Swedish
Nanologica's Rights Issue Registered - Conversion of BTA to Shares
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the registration of a rights issue with the Swedish Companies Registration Office, detailing the subscription rate (100%), the conversion of BTA (Paid Subscribed Shares) to ordinary shares, and the resulting changes in the number of shares and share capital. This directly relates to changes in the company's capital structure and fundraising activities. This fits the definition of 'Capital/Financing Update' (CAP). Although it mentions a resolution from an Extraordinary General Meeting, the primary focus is the successful completion and registration of the capital raise, not the voting results themselves (DVA) or a general announcement of a report (RPA/RNS).
2024-04-04 English
Nanologicas företrädesemission registrerad – omvandling av BTA till aktier
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that Nanologica AB's rights issue (företrädesemission) has been registered with the Swedish Companies Registration Office (Bolagsverket). It details the completion of the subscription, the amount raised (54.2 MSEK), the conversion of temporary shares (BTA) into actual shares, and the resulting changes in the number of shares and share capital. This type of announcement, detailing fundraising activities and capital structure changes resulting from a financing event, aligns best with the 'Capital/Financing Update' category. Although it is a formal announcement, the core subject matter is the successful completion and registration of a capital raise, making CAP more specific than a general RPA or RNS.
2024-04-04 Swedish
Change of Number of Shares and Votes in Nanologica AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document explicitly details a 'Change of Number of Shares and Votes' resulting from a completed rights issue. This involves an increase in the total number of shares (from 36,146,142 to 44,178,618) and a related resolution regarding share capital. This directly relates to changes in the company's capital structure and share count. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). Although it is a specific announcement, the core subject matter aligns perfectly with the SHA definition, rather than a general financing update (CAP) or a transaction in own shares (POS), as this was a rights issue to existing shareholders.
2024-03-28 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.